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Local recurrence after surgery for head and neck
squamous cell carcinoma (HNSCC) remains a com-
mon event associated with a dismal prognosis.
Improving this outcome requires a better under-
standing of cancer cell populations that expand
from postsurgical minimal residual disease (MRD).
Therefore, we assessed clonal dynamics in a surgical
model of barcoded HNSCC growing in the submental
region of immunodeficient mice. Clonal substitution
and massive reduction of clonal heterogeneity
emerged as hallmarks of local recurrence, as the
clones dominating in less heterogeneous recur-
rences were scarce in their matched primary tumors.
These lineages were selected by their ability to
persist after surgery and competitively expand from
MRD. Clones enriched in recurrences exhibited
both private and shared genetic features and likely
originated from ancestors shared with clones domi-
nating in primary tumors. They demonstrated high
invasiveness and epithelial-to-mesenchymal transi-
tion, eventually providing an attractive target for ob-
taining better local control for these tumors.
INTRODUCTION
Local recurrences after surgical removal of the primary tumor are
generally, and in particular in head and neck squamous cell car-2208 Cell Reports 25, 2208–2222, November 20, 2018 ª 2018 The A
This is an open access article under the CC BY license (http://creativecinoma (HNSCC) (Gath and Brakenhoff, 1999), suspected to
originate from minimal residual disease (MRD) left behind during
initial surgery. Cancer cells that have expanded beyond the
margin of the tumor as a consequence of the acquisition of an
invasive phenotype may potentially survive after therapy and
resume growth, giving rise to local recurrence. Some similarities
with cancer stem cells (CSCs) could be anticipated, because the
latter also have the ability to undergo an invasion-associated
epithelial-mesenchymal transition (EMT) and repopulate tumors
(Ye and Weinberg, 2015). The CSC model would imply that
recurrent tumors originate from a subset of CSCs likely exhibiting
more invasive properties and thus causing a more aggressive
disease than the primary tumor. In this respect, there is a striking
parallel with metastatic progression, which also relies on the
acquisition of an invasive phenotype (Liotta, 2016; Talmadge
and Fidler, 2010). Metastases, as suggested by experimental
work, appear to be driven by a stem-like cell subpopulation pref-
erentially seeding and growing atmetastatic niches (Liotta, 2016;
Talmadge and Fidler, 2010). The concept of rare metastasis-
forming (Talmadge and Fidler, 2010) or metastasis-initiating cells
(Celia`-Terrassa and Kang, 2016), which are related to CSCs,
could be hypothetically applied to recurrences. If true, local re-
currences could be initiated by rare CSC-like clones pre-existing
within the heterogeneous cancer cell population, disseminating
alone or as a collective (Cheung and Ewald, 2016) and undergo-
ing an evolutionary diversification (Turajlic and Swanton, 2016).
In this context, the rapidly developing concept of clonal hetero-
geneity (McGranahan and Swanton, 2017) would explain the
phenotypic evolution from a primary to a recurrent tumor by sur-
mising that a handful of clones within the primary cancer cell
population will disseminate and outgrow after surgery.uthor(s).
commons.org/licenses/by/4.0/).
Squamous cell carcinomas of the head and neck are aggres-
sive and deadly cancers (Marur and Forastiere, 2016) annually
affecting more than half a million people worldwide (Global
Burden of Disease Cancer Collaboration et al., 2017). The treat-
ment for these cancers typically consists of surgical removal, fol-
lowed by various adjuvant treatments, such as radiation therapy
alone or in combination with chemotherapy. This cancer is well
known for its capacity to locally recur, and it is undisputed that
these local recurrences are among the main reasons for patient
mortality (Gleber-Netto et al., 2015). Thus, HNSCC serves as an
excellent model to study the biology of local recurrences after
surgery. If locally recurring HNSCC truly originates from few or
single clones, adjuvant treatment of patients can be potentially
improved by combining non-specific therapies with a targeted
approach to specifically eliminate these cells.
To study local recurrence at a single-cell resolution, we devel-
oped a surgical model of HNSCC recurrence using red-green-
blue (RGB)-marked, genetically barcoded human cancer cells
(CAL27) able to grow invasively in the submental region of immu-
nodeficient mice. CAL27 cells were lentivirally labeled with a
combination of three fluorescent proteins (RGB panel) (Weber
et al., 2011), followed by DNA barcoding using a highly complex
lentiviral library (Thielecke et al., 2017). While fluorescent pro-
teins helped with image-guided surgery and were used to
approximate clonal composition by microscopy, genetic barco-
des permitted a precise clonal deconvolution using next-gener-
ation sequencing (NGS). Using this technology, we exhaustively
analyzed the cellular population contributing to local relapses in
HNSCC.
RESULTS
RGB Marking and Genetic Barcoding to Study Tumor
Clonality in a Mouse Model of Postsurgical HNSCC
Recurrence
The RGB-marked, barcodedCAL27 cell line (RGB32) was gener-
ated in two steps: a first large-scale transduction of CAL27 cells
with a mixture of mCherry, Venus, and Cerulean fluorescent vec-
tors resulted in the CRGB cell line, which was then modified by a
second large-scale transduction with the BC32 barcode library
followed by puromycin selection. The small proportion of bar-
code overlap between barcode sequencing (Bar-Seq) replicates
after retrieval from 200 ng of genomic DNA (corresponding to
3 3 104 cells) confirmed the high barcode diversity in the
RGB32 population (Figures S1A and S1B). In vitro culture of
RGB32 cells resulted in an enrichment of a subset of barcodes,
as shown by the frequency of the most dominant barcode in
each population increasing from 0.18% to 0.54% and 2.70%
after 1, 10, or 20 passages, respectively (Figure S1C). To
completely avoid any potential expansion bias in vitro, only early
passage RGB32 cells (p.2) were implanted inmice either alone or
together with HNSCC patient-derived cancer-associated fibro-
blasts (CAFs), known for their ability to promote tumor growth
and metastasis (Wheeler et al., 2014).
Upon implantation in the submental region of NMRI/nude
mice, RGB32 tumors showed HNSCC’s typical squamous differ-
entiation (Figure 1A) and a tendency toward increased growth
rate in the group with CAF co-implantation (Figure 1B, top). Tak-ing advantage of RGB colors, we performed image-guided mi-
crosurgeries (Figure 1C) to resect tumors as completely as
possible, although potentially leaving behind MRD as presumed
from the histological evaluation of sagittal sections from tumor-
bearing floor-of-the-mouth (FOM) (Figure 1A). Palpable recur-
rences started to grow in the majority (9/12) of operated mice
3–6 weeks after surgery. In this cohort, no lymph node (LN)
metastasis or pulmonary metastasis was observed in recur-
rent-tumor bearingmice. The growth kinetics of recurrent tumors
developing in the group of mice without human CAF co-implan-
tation was very consistent, in contrast to the group with co-
implanted CAFs that showed more diverse patterns of recurrent
tumor growth (Figure 1B, bottom).
Spectral Analysis Shows Reduced Heterogeneity in
Recurrent Tumors and Suggests Clonal Substitution
after Surgery
Live fluorescence imaging showed that primary tumors were
fragmented into differently colored areas and more heteroge-
neous than recurrent tumors (Figure S2A), thus hinting at poten-
tial clonal reduction after surgery. Next, sections from a set of
eight matching primary and recurrent tumor pairs were imaged
by fluorescence microscopy, demonstrating patterns of diverse
multicolored cellular areas in primary tumors, whereas recurrent
tumors usually consisted of few dominant colors organized in
larger patches (Figures 2A and S2B). Predictably, cell lines ex-
planted from a set of recurrent tumors retained the colors of
the dominant patches found in the tumor they originated from
(Figure 2A). In addition, the diversity of colors was noticeably
greater in differentiated areas (Figure 2B), indicating that a large
fraction of color-coded cells underwent terminal squamous dif-
ferentiation. Computer-assisted spectral deconvolution of the
previous images (Figures 2C, 2D, and S2C) revealed a surpris-
ingly high proportion of pixels colored with a hue specifically en-
riched in the recurrent tumors (up to 25.2%), suggesting that
their cellular composition had profoundly changed after surgery
(Figure 2D). At the tumor front and in the surrounding normal tis-
sue, several instances of lymphovascular invasion (LVI) by
apparently monoclonal groups of cancer cells were observed
(Figures 2E and 2F). In addition, the peritumoral area of the tumor
seemed more homogeneous than the intratumoral area, as re-
flected by the limited number of colors displayed by the clones
located at the tumor border (Figures 2E and 2G). These clones
found inside lymphatics and at the tumor border are likely candi-
dates remaining after surgery and contributing to recurrences.
Bar-Seq Confirms Substitution of Dominating Clones
after Postsurgical Tumor Regrowth
Quantification of barcodes by Bar-Seq revealed that the diversity
of clones (defined as the progeny of a single founder cell which
carries a unique barcode) found in primary tumors represented
on average 9.0% of the diversity of barcodes in the RGB32 refer-
ence cell line (mean = 9.0%; SD = 6.6%). This number further
decreased to about 0.2% of the reference in recurrent tumors
(mean = 0.21%; SD = 0.07%), indicating a stepwise and drastic
reduction of the clonal diversity from the original cell line to pri-
mary and recurrent tumors (Figure 3A). Notably, co-implantation
of CAFs (1 3 106 cells) slightly increased clonal heterogeneity inCell Reports 25, 2208–2222, November 20, 2018 2209
Figure 1. Surgical Mouse Model for Recurrent HNSCC
(A) H&E staining of a floor-of-the-mouth (sagittal section) from a RGB32 tumor-bearing mouse. T, tumor; Di, areas of squamous differentiation; MRD, minimal
residual disease, which stays with the adjacent muscular (M) tissue.
(B) Growth of primary (top panel) and recurrent tumors (bottom panel) following cell implantation and surgery. The number of implanted cells is indicated in the
bottom table (by cohort).
(C) The expression of fluorescent proteins by cancer cells allows sensitive control of the residual cells during and after image-guided microsurgery. See also
Figure S1 for details on the characterization of the RGB32 cell line.the corresponding group, raising the mean complexity from
9.0% to 19.0% (mean = 19.0%; SD = 11.4%) (Figure 3A). Similar
results were obtained when co-implanting CAFs (43 105) with a
higher number of implanted RGB32 cells (1.63 106) (Figure 3A).
Occurrence of the most abundant clone (first rank) in each
primary tumor (n = 8) varied from 3.2% to 31.2%, whereas it rep-
resented between 32.9% up to 99.6% of the whole sample pop-
ulation in recurrent tumors (n = 8) (Figure 3B; left). Strikingly, the
first-ranked clone in each recurrent tumor was always different
from the first-ranked clone in the matched primary tumor (Fig-
ure 3B; right), demonstrating that clonal substitution invariably
happened during the outgrowth of recurrent tumors. Bar graphs
displaying the relative frequency (in percent of the whole popula-
tion) of the top-five ranked barcodes found in each sample give a
sense of the clonal type of each tumor (Figures S3A–S3H). In 4 of
8 recurrent tumors, we observed the extreme overrepresentation
of a single, yet always different barcode (Figures S3A, S3B, S3E,
and S3G). The barcode composition from three explant cell lines
accurately reproduced the composition of their matching recur-
rent tumor (Figures S3F–S3H), even though we observed mar-
ginal expansion of some other clones (Table S1). This suggests2210 Cell Reports 25, 2208–2222, November 20, 2018that a number of ‘‘passenger’’ clones, including clones prevailing
in primary tumors, were carried over into recurrent tumors and
can be reactivated by in vitro culture of explant cell lines.
Next, we combined Bar-Seq data from eight primary and
recurrent tumor pairs in a global analysis and included barcodes
with total counts per million (CPMs) of at least 30,000 across
samples (Figure 3C; Table S1). The presence of multicolored
bars in this graph demonstrates that some clones (such as
R10, R137, or R140; Figure 3C, top panel) proficiently grew in
multiple primary tumors, which were all clonally more heteroge-
neous than recurrent tumors. Every largest clone in recurrences
(Figure 3C, bottom panel) only dominated in a single sample and
was clearly underrepresented in the respective primary tumors,
with the exception of R12 and R3 that were ranked second
(4.77%) and fifth (2.41%) in their primary tumor, though repre-
senting small fractions (Table S1). To functionally designate the
founding cells of the dominating clones in primary and recurrent
tumor samples, from here on we refer to them as tumor-initiating
clones (TICs) or recurrent TICs (RTICs), respectively. Notably,
several clones ranked first in recurrences were also detected,
although in minor quantities, across multiple primary (e.g., R2
Figure 2. Spectral Analysis of Xenografted HNSCC Tumors
(A) Multicolor fluorescence microscopy of matched primary tumors (left), recurrent tumors (middle) and recurrence-derived explant cell lines (right).
(B) Higher magnification image of a representative primary tumor showing a highly diversemulticolor area of differentiation (asterisk) next to amore homogeneous
non-differentiated area of the tumor (triangle).
(C) Spectral distribution of hues inmicroscopy images shown in (A). In these deconvolution plots, each pixel from the original picture is plotted according to its hue
value (azimuthal coordinate) and its color saturation value (radial coordinate). Overlaying hues specific for primary or recurrent tumors after transformation in a
green or a magenta mask respectively shows a high percentage of recurrence-specific hues.
(legend continued on next page)
Cell Reports 25, 2208–2222, November 20, 2018 2211
in 5 and R12 in 8 tumors) or recurrent tumors (e.g., R3 in 6 and
R12 in 8 tumors, but both were truly dominant in only one
case) (Figure S3I). Thus, our data strongly suggest that certain
competitive clones, which are usually underrepresented in pri-
mary tumor bulk, are equipotent to seed recurrent tumors.
Statistical Modeling of Tumor Resection
We raised the question whether and under which circumstances
a subset of initially minor clones (RTICs) can ultimately dominate
in the recurrent tumor. First, we statistically addressed this ques-
tion by a quantitative estimation of the surgical process. Under
the most naive assumption about the nature of the original tumor
one could argue that all cells of all clones were equipotent and
homogenously distributed. We approximated that only 1,000
cells remain from an initial tumor of 25 3 107 cells and further
adhered to the conservative estimation that up to 25% of all cells
represent potential RTICs (usually, we only observed a much
smaller frequency), which are homogenously distributed in the
initial tumor. Defining this setting as the null hypothesis (i.e.,
no spatial correlation of the clones), the extremely low probabil-
ity < 106 indicated that the enrichment of those RTICs to more
than 80% in the recurrent tumor is virtually impossible only
based on the sampling process (see details in the STAR
Methods). Therefore, a homogenously mixed tumor could be
excluded, while a spatial correlation of the seeding clones
(including potential RTICs) appeared as a plausible alternative
hypothesis. To further substantiate this notion in a second
step, we contrasted the unlikely homogeneous scenario with
an alternative setting in which clones are spatially confined but
still, all cells are equipotent (Figure 3D). Using this schematic rep-
resentation and sampling cells from the hypothetical MRD, the
alternative scenario was much closer to the experimentally
observed, reduced heterogeneity in recurrent tumors, while we
found a distinctly higher clonal heterogeneity in the homoge-
neous scenario. This finding confirmed that random selection
from a homogeneous mixture of equipotent clones is highly un-
likely as a mechanism to promote the outgrowth of few RTICs,
and that other mechanisms, like the spatial correlation of the
seeding clones beyond the tumor periphery or a competitive
growth advantage, need to be considered.
RTICs Are Enriched at the Primary Tumor Periphery and
in the Tumor Beds
The observed distribution of color-coded cells in primary tumors
suggests that some clones are more prominent at the tumor pe-
riphery (Figures 2E and 2G). These cells could include potential
RTICs. To compare the clonal composition of peritumoral and in-
tratumoral areas, we selected five primary tumors for which the
composition of the recurrent tumor was already assessed by
Bar-Seq and performed laser microdissection followed by Bar-(D) For each mouse, the proportion of hues shown in (C) (and also in Figure S2C
between matched tumors (black) is indicated as a percentage of the total numbe
(E) Lyve-1 immunofluorescence staining in an RGB32 primary tumor showing
arrowhead indicates Lyve-1 positive lymphatic vessels.
(F) Further examples of Lyve-1 immunofluorescence staining showing instances
(G) Representative image from a primary tumor showing amore uniform color in the
evident in E).
2212 Cell Reports 25, 2208–2222, November 20, 2018Seq analysis. Next, we scored each retrieved barcode for being
enriched in the peritumoral area and in recurrent tumor. Although
tumor edges were found to be colonized by multiple clones,
including those that prevailed in the tumor mass (e.g., R10), we
observed a significant enrichment of R2, R3, and R12 RTICs at
the edges of primary tumors (Figure 3E). However, being en-
riched does not mean that these clones were the most abundant
at the tumor front. For example, R3 accounted for 0.44% of the
peripheral clones in mouse m407, whereas the most abundant
clone (R2594) was approximately a hundred times bigger
(constituting 41% of all clones at the periphery) (Table S1). Yet
after surgery, only R3 was found in m407R recurrent tumor,
whereas none of the 11 more abundant clones at the periphery
was detected. This proved that abundance at the edge was
not sufficient to propagate into the recurrent tumor. It might
be speculated that further dissemination is required to initiate
recurrence, potentially through deeper invasion in surrounding
tissue or LVI.
To find out which clones were seeding outside the tumors, we
analyzed the clonal composition of seven primary tumors and
matching underlying muscular layers of the FOM (i.e., surgical
tumor beds) from RGB32-implanted mice. We expected to
detect some clones previously identified as enriched in recurrent
tumors. Barcodes that were detected in at least 2 of 7 tumor
beds and had positive enrichment scores (log ratio between
read counts in the tumor bed and the matched primary tumor)
in at least one of them are presented in a heatmap (Figure 3F).
As anticipated, R3 (RTIC previously identified in mouse m407)
was enriched in mouse m576, representing, respectively,
0.01% and 11.43% of the population in the primary tumor and
its surgical bed. Notably, although never dominating in any of
the eight recurrent tumors previously analyzed, R10 was identi-
fied in 5 of 7 tumor beds and was thus the most common clone
in surgical beds (Figures 3F and 3G). Mirroring the clonal substi-
tution observed between primary and recurrent tumors, the first-
ranked clone in each tumor bed was always different from the
first-ranked clone in the matched primary tumor (Figure 3H).
Although this analysis has confirmed the enrichment of some
clones, it very likely underestimates the total complexity of
the disseminated population, as clones located beyond the
analyzed muscular layer may be missed. In summary, multiple
clones remain after surgery in the tumor beds and potentially
compete in the MRD for regrowth.
Recurrence-Initiating and Invasive Properties of Clones
Dominating in Recurrent Tumors
To test whether the ability to initiate recurrence is preserved in
recurrence-derived explants, we reimplanted the explants in
mice. All but one explant demonstrated an increased tumor
growth rate (especially 407R) and a quicker onset of postsurgical) specific for primar7y tumors (green), recurrent tumors (magenta), or shared
r of hues.
lymphovascular invasion (LVI) just outside of the primary tumor mass. The
of intratumoral LVI. Arrowheads indicate Lyve-1 positively lymphatic vessels.
peritumoral area compared to themore heterogeneous intratumoral area (also
(legend on next page)
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recurrenceswhen compared to parental RGB32 cells (Figure 4A).
In addition to R3 (from explant 407R), recurrence-initiating ca-
pacity was also confirmed for R2 and R19 (both constituting
explant 411R) as well as R7 (from explant 293R), while other
abundant clones in explant 293R (R5/R11/R25) failed to initiate
second-generation recurrences (Figure 4B). These data indicate
that recurrence-initiating capacity is limited to few clones and
greatly varies between competitive clones, suggesting that
some clones identified in recurrences could be ‘‘passenger’’
ones. Other less abundant ‘‘passenger’’ clones remained scarce
in the reimplanted tumors and with few exceptions went
completely undetected in second-generation recurrences (Fig-
ure 4B; Table S1). The most aggressive phenotype was
observed for explant 407R (enriched in R3), which was not only
quickly growing as a new primary tumor, but was also able to
initiate a multinodular, highly invasive recurrence metastasizing
into the neck lymph node (Figure 4C). Furthermore, explant
407R demonstrated prominent invasive behavior in organo-
typic co-cultures with immortalized CAFs (Figures S4A–S4D).
Compared to RGB32 cells, admixing of explant 407R with
CAL27 (at ratio 1:4) thickened the organotype’s invasive layer
at the expense of the basal layer (Figures S4A and S4B). In addi-
tion, whereas RGB32 cells were present throughout all layers
and slightly enriched in the differentiated layer, 407R cells were
almost exclusively restricted to the invasive layer (Figures
S4C–S4D), illustrating a stronger invasive potential of these cells
compared to the heterogeneous parental population. Thus, the
recurrence-initiating potential seen in a limited number of clones
(RTICs) was very likely related to their unique ability to acquire an
invasive phenotype.
Progressing EMT in RTICs
To investigate the invasion-related properties of RTICs, we
focused on EMT. Expression of vimentin, a mesenchymal
marker, by a fraction of cancer cells in primary and recurrent tu-
mors (Figures S4E and S4F) indicates that these cells were able
to undergo EMT. The EMT phenotype clearly progressed be-
tween the first and second generations of explants (after reim-
plantation), as evident by a significant increase in expression ofFigure 3. Clonal Substitution in Recurrent HNSCC Tumors
(A) Clonal complexity of primary tumors with (n = 7) or without (n = 3) co-implanta
(n = 3). Boxplots indicate the relative numbers of individual barcodes identified
reference RGB32 cell line after normalizing to the sequencing depth of each cor
(B) The cellular contribution of the most abundant clones to the bulk of barcodes o
abundant clones in matching primary and recurrent tumors illustrates a clonal su
(C) Bars indicate barcodeswith total counts permillion (CPMs) of at least 30,000 ac
and the bottom panel depicts clonal distribution in recurrent tumors (see also Fig
(D) Schematic illustration of two different scenarios for spatial clonal distributions
representative clones, and cells from the same clones are spatially confined in
represent 1% of the total area, the boxplots quantify the level of clonal diversity in
confined clones.
(E) Scatterplot highlighting the correlation between the enrichment of clones at th
(recurrence score). R2, R3, and R12 represent RTICs enriched at the tumor perip
(F) Heatmap showing all clones able to disseminate in the muscle of at least two an
in the heatmap correspond to missing values (meaning that the barcode was no
(G) Bars indicate the relative frequency of the top-five clones in each matched p
different colors and the most abundant barcodes are explicitly labeled. The sum
depicted in gray.
(H) The frequency of the most abundant clones in matching primary tumors and
2214 Cell Reports 25, 2208–2222, November 20, 2018the EMT transcription factors ZEB1 and SNAI2 (Figure 4D) and
by a progressive loss of E-cadherin (Figure 4E) in second-gener-
ation explants. Furthermore, when compared to parental RGB32
cells or to the first-generation explant 293R, both SLUG (SNAI2
product) and ZEB1 proteins accumulate in the nuclei of the sec-
ond-generation explant 578R (Figures S4G and S4H). We
reasoned that the EMT phenotype of RTICs might represent a
promising therapy target. Indeed, we found improved recur-
rence-free survival of CAL27 tumor-bearing mice treated with a
combination of neo-adjuvant and adjuvant administration of
the c-MET/ALK inhibitor crizotinib (Figure S4I), an observation
deserving further investigations.
Expression of Cell-Surface Protein CD10 Is Shared by
Some TICs and RTICs
To identify potential markers of RTICs and prospective targets
for therapy, we performed membrane-enriched proteomics
analysis (Zougman et al., 2014) using parental cell lines and
recurrence-derived explants. Remarkably, 407R cell line distinc-
tively expressed membrane-associated MME (CD10) as well as
higher levels of EGFR protein, which was constitutively phos-
phorylated on residue Y1068 in a serum-independent fashion
(Figure 5A). CD10 is a CSC marker in HNSCC (Fukusumi et al.,
2014) and hence is a good candidate marker for RTICs. We
anticipated that cell-surface expression of CD10 in 407R cells
(enriched for R3 RTIC) could be used in combination with R3
intrinsic color to isolate this clone from the RGB32 population
(Figure 5B). Indeed, R3 (5.1%) as well as other RTICs (such as
R2 and R19) and unexpectedly also R10 (8.9%; defined as tu-
mor-initiating clone, TIC, because of its observed relative preva-
lence in primary tumors) (Figures 3C and 3G) were detected in
the sorted CD10high fraction of RGB32 cells (Table S1). Surpris-
ingly, R2, R3 and R19 clones vanished after in vitro culture of
both CD10high and CD10high/PEhigh subpopulations, whereas
R10 remained as the most abundant clone (2.4% and 21.6%;
Table S1). Tumors established by cultured CD10high subpopula-
tion grew faster as compared to CD10low subpopulation (Fig-
ure 5C) and were dominated by R10 (between 35.5% and
77.2%; Figure 5D; Table S1). In two mice from the CD10hightion of CAFs, recurrent tumors (n = 8) and recurrence-derived explant cell lines
in each sample compared to the total number of individual barcodes of the
responding library. p, p value.
f each tumor is indicated by a boxplot (left panel). The frequency of these most
bstitution (right panel).
ross samples. The top panel indicates the clonal distribution in primary tumors,
ures S3A–S3H). Individual mice are color-coded.
. The top-left setting contains a spatially uniform distribution of cells from 400
the top-right scenario. Considering the abundance of clones in the MRD that
the MRD over 100 simulations, which is reduced for the scenario with spatially
e tumor periphery (peritumoral score) and their enrichment in recurrent tumors
hery and in recurrences.
imals, with a positive enrichment score for at least one of them. The black cells
t found in this sample, neither in the tumor nor in the surgical bed).
rimary tumor and muscle. For each mouse, different barcodes are shown by
of all barcodes that are ranked below the top-five most abundant clones is
tumor beds illustrates a clonal substitution.
Figure 4. Selection of Pro-EMT Features and Aggressive Phenotype by Reimplantation of Recurrence-Derived Explant Cell Lines
(A) Tumor growth curves following reimplantation of recurrence-derived explant cell lines as compared to mice injected with the parental RGB32 cell line. The
dashed lines indicate the average growth (by loess regression) of RGB32 tumors reported in Figure 1B.
(B) Clonal evolution of recurrence-derived explant cell lines following reimplantation in mice. The contribution of clones dominating in the original recurrence and
explants (left) is largely maintained in the newly developing tumors of three independent mice per explant cell line (middle). The rate of recurrence (second-
generation recurrence) following surgery is indicated for each explant (right). One mouse was sacrificed before surgery (y). Where possible (expected monoclonal
sample), NGS was substituted by Sanger sequencing (S).
(C) Fluorescence imaging of an aggressive recurrence (407R/m581) with multinodular growth, deep invasion in tissue and LN metastasis.
(D) qRT-PCR expression profiles for the EMTmarkers ZEB1 andSNAI2 in a series of parental cells (CAL27, CRGB, RGB32), first-generation explants (293R, 407R,
411R), and second-generation recurrence explants (derived in B, n = 6 explants). p, p value.
(E) Immunoblot analysis of E-cadherin in the original RGB32 cell line and first- and second-generation recurrence explants (derived in B). Relative E-cadherin
signal (relative to GAPDH) was calculated and is indicated below. In addition, a longer exposure for E-cadherin is presented at the bottom.
See also Figure S4.group, R10 quasi-monoclonal recurrences (tumor and LN
metastasis) and one additional polyclonal, R10-poor (0.3%)
recurrent tumor developed after surgery. Single-clone enriched
recurrences also developed in two mice with CD10low tumors,
showing clonal substitution in m669 mouse but regrowth of the
dominant clone in m670 mouse. Taken together, expression of
a common marker, i.e., CD10, between a subset of TICs (repre-
sented by R10) and RTICs indicates that they may have a
common origin, and thus share the proficiency to initiate post-surgical recurrences. However, this recurrence-initiating apti-
tude seemed regulated by external factors such as the overall
cellular complexity.
RTICs Show Private and Shared Genetic Features
To find out whether the recurrence-initiating capacity is related to
a certain genetic profile, we performed exome-seq analysis of
parental (n = 3) and explant cell lines of the first- (n = 3) and sec-
ond-generation (n = 9) recurrent tumors. These explants includedCell Reports 25, 2208–2222, November 20, 2018 2215
Figure 5. CD10 as a Marker of Cells with Tumor-Initiating Potential
(A) Immunoblot analysis demonstrating CD10 and EGFR overexpression as well as EGFR autoactivation in explant 407R as compared to parental cell lines and
other explants.
(B) Fluorescence-activated cell sorting (FACS) analysis of CD10high sorted cells before in vivo implantation. Despite some plasticity, a significant fraction of cells
retained high expression of CD10.
(C) Growth curve of primary tumors following implantation of CD10high or CD10low cells showing acceleration of the growth kinetics in mice implanted with
CD10high cells.
(D) Clonal distribution in mice implanted with CD10high or CD10low cells. Bars indicate the relative frequency of clones in corresponding primary and recurrent (R)
tumors. For each mouse, different barcodes are shown by different colors. S, analyzed by Sanger sequencing. LN, recurrence located in the neck lymph node
area. Sk, recurrence located in the neck skin.quasi-monoclonal RTICs (R2, R3, R7, and R19) and the quasi-
monoclonal R10 TIC. Our CAL27 stock and its two subsequent
derivatives (CRGB and RGB32) showed concordance in 52 of
54 CAL27-specific SNPs retrieved from theCCLE database, con-
firming relatively high genomic stability in our cell lines (Fig-
ure S5A). The genomic landscape of each explant is presented
in Figure 6.When compared to RGB32,most explants were char-
acterized by a modest change in the alternate allele frequency
(AF) of the identified variants (Table S2; single-nucleotide varia-
tions [SNVs]; Figure 6A), while explants enriched in R3 showed
extensive allelic variations, segregating this clone from the
parental population. However, more than half of the CAL27 spe-
cific SNPs, including those in TP53 and TGFBR1 genes, were
preserved and hence confirmed the shared clonal origin of R3
and the rest of the parental population (Figure S5A). Few private
(e.g.,PRKG2R282T in R19) or shared (e.g.,RNF123M1087I in R2
and R7) variants were identified for a series of RTICs (Figure 6A).
In addition, private heteroplasmic variants were found in mito-
chondrial DNA (mtDNA) of RTICs, such as C114T and G225T2216 Cell Reports 25, 2208–2222, November 20, 2018(both in D-loop region) in R3 and R7, respectively, and MT-ND1
C3946T (E214*) shared mutation in R2, R7, and R19 (Table S2).
On a chromosomal level, explant cell lines showed both
shared and private gains and losses of focal or sub-chromo-
somal nature (Table S3; copy number variations [CNVs]; Fig-
ure 6B). Interestingly, a regional gain on chromosome 20p, which
contains PCNA gene (among others), was shared between four
RTICs (R2, R3, R7, and R19) (Figure 6B). An additional allele of
PCNA gene could theoretically confer a proliferative advantage
to RTICs during their outgrowth from MRD. In addition, a region
including the known tumor suppressor geneMYH9 (on chromo-
some 22) (Schramek et al., 2014) was lost in R19 (Figure 6B).
Remarkably, second-generation explants either derived by
in vitro culture or in vivo growth showed a minimal number of
novel mutations and aberrations compared to first-generation
explants, even in the case of the explant derived from a LN
metastasis. In particular, R19 enriched either by cell sorting
(411R/Velo) or in the second-generation explants (585R) showed
highly concordant genetic profiles (Figure 6A). Indeed, only five
Figure 6. Characterization of Recurrence-Derived Explants by Whole-Exome Sequencing
(A) Heatmap comparing the alternate AF of all SNPs identified in reference (CAL27, CRGB, and RGB32) and explant cell lines. Explant names are indicated on the
left side of the heatmap, and major barcodes constituting these explants are indicated on the right. Heterozygous (for R10) or homozygous (for R3) wild-typing of
the SMAD4 Q245* variant and private mutations for other clones are indicated at the bottom.
(B) CNV analysis across the explant cell lines calculated using CODEX R package following exome sequencing. Each column shows a representative private or
shared regional DNA alteration. The y axis represents the copy number and is approximated by the logarithmic ratio of CODEX normalized counts divided by raw
counts.
See also Figure S5.novel variants were detected (all at a frequency below 0.31) in
explant 585R when compared to the sorted 411R/Velo explant
(Table S2). Similarly, only eight novel variants were detected
(all at a frequency below 0.16) when comparing R3 detected in
the first- (407R) and second-generation explants (581R-A and
581R-LNM) (Table S2).
R3 and R10 Clones Belong to the Same Lineage
Beyond the fact that R3 and R10 express CD10, there was a
gradual increase in the absolute allelic distance (i.e., the differ-ence in alternate AF between a subject and its reference) from
the parental RGB32 cell line to R10 explants and to R3 explants.
In particular, R3was featured by complete wild-typing ofSMAD4
Q245* mutation, whereas R10 was heterozygous for this variant
(Figure 6A). Consistently, while SMAD4 was undetectable in
CAL27 parental population, its expression was restored in ex-
plants enriched in R3 and R10 or in sorted CD10high cells (Fig-
ure S5B). Notably, reconstitution of SMAD4 was not sufficient
to convey TGF-b pathway signaling (Figure S5C), hence indi-
cating a non-canonical function of SMAD4. CD10 and EGFRCell Reports 25, 2208–2222, November 20, 2018 2217
were also prominently expressed by R10 and CD10high cells (Fig-
ure S5B), further supporting the likelihood of a common ancestor
for R10 and R3 in the CAL27 population. Thus, we reason that
such ancestor clone bearing SMAD4 wild-type (WT) allele per-
sists in CAL27 cell culture, and we suspect that R10 precedes
R3 in the clonal evolution. This hypothesis is further supported
by (1) a progressing gain in regions encompassing EGFR (chro-
mosome 7) and MME (chromosome 3) genes in R10 and R3 as
compared to RGB32 cells (Figure 6B), (2) an increasing wild-
type frequency of nonsynonymous mutations in genes located
in a 45-Mb region on chromosome 4, a 54-Mb region on chromo-
some 5 and a 43-Mb region on chromosome 8 in R10 and R3 as
compared to RGB32 cells (Figure S5D), and (3) the presence of a
heteroplasmic C114T variant in mtDNA of R3, but not R10 (Table
S2). Furthermore, a set of private variants supports a divergent
evolution of R3 and R10 from a common ancestor: while gains
encompassing CDH13 (chromosome 16) and CRK genes
(chromosome 17) were found in R3, losses including HIPK3
(chromosome 11) and RUNX1 (chromosome 21) genes were
characteristic for R10 (Figure 6B). Altogether, the genetic anal-
ysis of R3 and R10 clones indicates that tumor-initiating clones
with different potential to outgrow in recurrences may arise dur-
ing tumor evolution from common, genetically unique ancestors
that substantially differ from other subclonal lineages.
DISCUSSION
Permanent cell marking has become an extremely useful tool
to study clonal dynamics (Blundell and Levy, 2014). In the pre-
sent study, we further advanced the joint application of RGB
marking and DNA barcoding (Cornils et al., 2014) for clonal
tracking by two modifications. First, based on the separation of
RGB and barcoding vectors we ensured the presence of unique
barcodes in single marked cells. Second, we exploited an
improved BC32 barcode running on a high level of complexity,
thus limiting the systematic bias inherent to previous techniques
(Thielecke et al., 2017) and making it the appropriate tool to
perform clonal deconvolution in highly heterogeneous cancer
cell populations.
Using cellular barcoding, we provide a comprehensive clonal
analysis of matched primary and recurrent tumors in a surgical
mouse model of HNSCC, and we highlight a distinct nature of
clones prevailing in postsurgical local recurrences. Initially, these
clones successfully propagated into the adjacent tissue remain-
ing after surgery, which can be viewed as a potential niche host-
ing the residual malignant cells. These cells constituting theMRD
are clinically undetectable by conventional intraoperative micro-
scopic evaluation. In HNSCC patients, even though both
mucosal and deep surgical margins may prove free of malignant
cells microscopically, the risk of recurrences is particularly
increased with detection of tumor-specific TP53 mutations in
the margin tissue (Brennan et al., 1995; Pena Murillo et al.,
2012). This, together with predominant correspondence of
TP53 mutations between primary HNSCC tumors and matched
recurrences (Hedberg et al., 2016; van Ginkel et al., 2016), sug-
gests that the latter may originate from pre-existing, invasive lin-
eages. These stem-like malignant cells could be endowed not
only with high invasive potential but also competency to repopu-2218 Cell Reports 25, 2208–2222, November 20, 2018late tumors starting from few residual cells. Our data support this
concept by providing evidence that a limited number of clones
spread and undergo further selection resulting in the outgrowth
of recurrences with a greatly reduced clonal diversity.
Although many aspects of clonal identity and dynamics, in
particular mechanisms of clonal interactions, migratory activity
and fitness within a complexmilieu of invasively growing HNSCC
tumors and postsurgical MRD remain to be elucidated, we
attempted to summarize our current understanding of postsur-
gical progression in HNSCC as a hypothetical model (Figure 7).
In this model, the co-occurrence of neutral and non-neutral
mechanisms of selection taking place in concert in the MRD
could be a rational explanation for the phenotype of clonal sub-
stitution observed in our data. Based on their ability to initiate
well-differentiated squamous primary and recurrent tumors, we
defined clones that prevailed in individual primary tumors as
TICs and clones that substantially contributed to the postsur-
gical recurrences as RTICs. The remaining sparse clones in pri-
mary tumors (defined as non-TICs) vanished during tumor
growth probably going from a transient proliferation state to a
terminal squamous differentiation state. Such categorization of
clones is not necessarily restricted to a pre-existing segregation
into respective branches, but may possibly have a conditional
nature, as it is expectedly influenced by the overall clonal
complexity, i.e., by the magnitude of interclonal interactions
and competition during tumor growth and by specific signals
produced by the tumor microenvironment. Dominance of certain
clones in the recurrences could be potentially attributed, as our
results suggest, to special genetic traits. However, such domi-
nance also can be possibly caused by a conditionally enhanced
ability to seed around the tumor by migratory activity or
lymphatic dissemination.
We hypothesize that clones that reached the tumor periphery
either by directed migration or by chance (e.g., as accidental fol-
lowers of migrating leader cells or due to a fortuitous location
during tumor growth) might compete for growth and experience
unbalanced proliferative activity resulting in clones of unequal
sizes at the tumor edges. Thus, the incidence of peritumoral
seeding could be biased toward more abundant clones located
at the tumor front. This could be true, if clones enriched at the
front are equipotent to spread. However, the ability to spread
by invasion may differ within peripheral clones and thus be the
most critical prerequisite for a clone at the tumor edge to even-
tually contribute to the outgrowth of tumor after surgery. Invasive
cells settled around the tumor and remaining after surgery may
resume growth and generate nests of either spatially linked or
separated clones, which can further undergo either neutral or
directed selection for one or few winner clones, which are the
fittest to establish recurrent tumors. Such interclonal interactions
may include both (1) competition between clones with different
potential to grow under conditions that differ from what they
experienced in primary tumor and (2) non-selective regrowth of
one or few clones at the expense of other functionally equal
clones. Any clone that managed to contribute to the initial stage
of residual disease (i.e., peritumoral seeding followed by
resumed proliferation) may not necessarily vanish as a conse-
quence of competitive interactions, but can remain as low-abun-
dant passenger with a negligible contribution to the postsurgical
Figure 7. Proposed Clonal Model
All CAL27 cells in the original human tumor are
anticipated to be of clonal origin and share a
number of clonal mutations (e.g., in TP53). Within
the tumor, different subclonal populations defined
by additional genetic alterations coexist and some
of them might come from a common lineage.
Cellular barcoding then results in a series of
clonally expanded founder cells. Depending on
the heterogeneity of the tested cell population at
the time of transduction, the barcoding step in
principle might result in the labeling of several
identical, i.e., clonally derived, cells with different
barcodes (barcode A, barcode B), though the
resultant barcoded cells will at least differ by their
respective viral integration sites. After implantation
of barcoded founder clones in mice, tumors
showed enrichment for a few proliferating clones
(TICs) and a very low frequency of one or few
clones that became dominant after regrowth
from the MRD (RTICs), while most of the founder
clones were not tumorigenic (non-TIC, NT). Cells
contributing to recurrences need to overcome two
barriers. First, theymust leave the tumormass and
disseminate in the MRD to escape from the
extensive surgical resection. Next, TICs andRTICs
are likely subjected to both neutral and directed
clonal interactions in the MRD. Whereas directed
selection could potentially prevent TICs from growing out of the MRD, the selection of RTICs that ultimately dominate in the recurrences could be the result of
neutral selection between clones with equal recurrence-promoting potential. Tumors developing from both TICs and RTICs have the ability to commit various
numbers of cells to terminal squamous differentiation (shaded areas).recurrence. However, such clones may potentially contribute to
the clonal evolution of the tumor, if adjuvant therapy (e.g., che-
moradiation) follows the surgery.
It is tempting to speculate that tumor microenvironment, in
particular via the supply of cancer cells with hepatocyte growth
factor (HGF) (Knowles et al., 2009), epidermal growth factor
(EGF) (Zhang et al., 2014), or transforming growth factor b
(TGF-b) (Oshimori et al., 2015) could possibly change the clonal
landscape of the invasively growing tumor, influence the pheno-
type of clonal populations at the tumor front and confer survival
benefit to residual cells. In particular, stromal factors may
induce some phenotypic plasticity in cancer cells, including
acquisition of EMT traits. It was shown that EMT in HNSCC,
like in other carcinomas, could be, in particular, induced by
HGF provided by fibroblasts in the tumor stroma (Knowles
et al., 2009) or hypoxia (Gammon and Mackenzie, 2016), a con-
dition that residual cells may experience at their niches. After
surgery, residual cells will be exposed to tissue-remodeling fac-
tors released during postsurgical wound healing, known to pro-
mote tumor growth and metastasis (Ceelen et al., 2014). The
combination of wound-associated factors, in particular EGF-
like factors that stimulate the proliferation of EGFR-overex-
pressing HNSCC cells (Licitra et al., 2011) and the inherent
ability of residual clones to compete for survival within this envi-
ronment, could collectively select for the fittest clone(s) with
tumor-initiating potential.
Genetic analysis indicates that clones massively enriched in
postsurgical recurrences could represent lineages that emerged
either independently during tumor evolution or that originated
from a very early ancestor, whose progeny may share manycommon features, such as stemness and invasiveness. For
example, in the parental CAL27 population, cells featured by
wild-type alleles of SMAD4 gene very likely originated from an
early ancestor heterozygous for SMAD4 mutation (represented
by clone R10), from which numerous descendants evolved to-
ward homozygosity of mutant SMAD4 allele, whereas a small
fraction of daughter cells preserved the wild-type allele (repre-
sented by clone R3). Such separation between ancestral
branches and their progeny could possibly have resulted
from chromosomal segregation errors causing asymmetric dis-
tribution of wild-type and mutant alleles. Chromosomal rear-
rangements known to accompany tumor progression by fueling
cancer evolution and adaptation (Sansregret and Swanton,
2017) may eventually cause the emergence of genetic variants
with a higher potential to seed and establish recurrences after
resection of highly heterogeneous tumors.
Although our barcoding technology unambiguously revealed
clonal substitution after resection of RGB32 tumors, previous re-
ports inferring clonality from variant allele frequencies in patient
samples showed a similar succession of dominant lineages in
recurrent cancers, such as acute myeloid leukemia (Ding et al.,
2012), T cell acute lymphoblastic leukemia (Kunz et al., 2015),
breast cancer (Hoadley et al., 2016), and glioma (Johnson
et al., 2014). In addition, rare pre-existing clones selected by
surgery and radiotherapy were identified in a mouse model of
recurrent medulloblastoma (Morrissy et al., 2016). Although po-
tential adjuvant therapy would also contribute to clonal substitu-
tion in recurrent tumors, we clearly show that surgery alone
results in a more homogeneous, sometimes nearly monoclonal
postsurgical recurrence, as compared to the primary tumor.Cell Reports 25, 2208–2222, November 20, 2018 2219
Consequently, personalized therapies targeting such clonal
populations might be developed into a successful treatment
approach in the future. In this context, the identification of EMT
as one of the common pathways exploited by clones enriched
in recurrent tumors provides a rationale for pharmacological in-
terventions. The reduced incidence of postsurgical recurrences
in the CAL27 model after treatment with crizotinib strongly sup-
ports the pivotal role of EMT, at least EMT initiated via c-MET, in
the outgrowth of recurrent tumors and exemplifies a possible
strategy to prevent recurrences.
Although our mouse model is unrivaled for the tracking
of clonal populations contributing to tumor regrowth after sur-
gery and testing of specific targeting approaches, it is limited
by the low rate of LN metastasis and the absence of distant
metastatic disease, representing other typical features of
HNSCC. Despite these shortcomings, our work serves to
build a working model explaining clonal events after surgery
and as a proof of technology, which can be transferred to
other surgical models of HNSCC for clonal tracking of LN and
distant metastasis. In conclusion, we believe that the system-
atic study of clonal events implicated in the development of re-
currences after surgery will greatly facilitate the establishment
of therapies urgently needed to improve survival of HNSCC
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All mouse experiments were approved by the Ethics Committee for Animal Experimentation of Switzerland and performed following
institutional guidelines. Eight-week-old female NMRI/Nude mice (JANVIER LABS, Le Genest-Saint-Isle, France) were used to
generate HNSCC tumors growing in the submental region as previously described (Behren et al., 2010). Cell implantation, microsur-
gical tumor resection, treatment with Crizotinib (PF-02341066, Active Biochem) and postsurgical follow-up including tumor sampling
for histology, microscopy and barcode analysis are described below.
Cell culture and generation of cell lines
Human CAL27 (ATCCCRL-2095) cell line was purchased from ATCC and authenticated by STR profiling (Microsynth). CRGB cell line
was generated using our established protocol for RGB marking (Weber et al., 2011, 2012). RGB32 cell line was derived from CRGB
cell line by lentiviral transductionwith a library of LeGO-eBFP2-2A-Puro-BC32 high-complexity DNAbarcodes. Detailed protocols for
generation of CRGB and RGB32 cell lines, explant cell lines from tumor-bearing mice and cell lines sorted by FACS are provided in
the Method Details.e2 Cell Reports 25, 2208–2222.e1–e7, November 20, 2018
METHOD DETAILS
Generation of barcoded cells (see also Figure S6A)
Parental and derivate cell lines were maintained in DMEM + GlutaMAX (GIBCO 31966) supplemented with 10% FBS (GIBCO
10270106) in a humidified atmosphere of 5% CO2 at 37
C. CRGB were generated from CAL27 using our established protocol for
RGB marking (Weber et al., 2011, 2012). In brief, high-titer preparation of LeGO vectors encoding mCherry, Venus, or Cerulean
were produced as described (Weber et al., 2008, 2012). CAL27 were plated at 0.5 3 106 cells/well in 6-well plates, and a total of
18 3 106 cells were subjected to RGB marking (day 1). At day 4, cells were pooled and analyzed for fluorescent protein expression
by flow cytometry. Frequencies were: 56.3% mCherry+, 51.2% Venus+ and 48.1% Cerulean+, indicating optimal RGB labeling.
Pooled cells were expanded in T75 cell culture flasks. At day 12, RGB-marked CAL27 were again pooled and fluorescence-positive
(red or green or blue) cells were sorted by FACS (> 99% purity). On day 19, 12 3 106 CRGB cells were transduced with a library of
LeGO-eBFP2-2A-Puro-BC32 high-complexity DNA barcodes. The vector library was generated as described (Thielecke et al., 2017).
To facilitate detection and selection of successfully transduced cells, this new barcoding vector encodes a blue fluorescent protein
(eBFP) coupled to a puromycin resistance gene via a 2A sequence. At day 22, a transduction efficiency of 4%was determined based
on eBFP expression indicating single vector integrations (Kustikova et al., 2003), i.e., unique barcodes in each cell. Resulting bar-
coded RGB-labeled CAL27 (designated as RGB32) were selected with puromycin.
Based on the data from the previous RGB marking and titration experiments (not shown), it has been clear that CAL27 cells are
easy-to-transduce. In fact, transduction was readily titratable over a wide linear range. As previously shown, based thereon it can
be concluded that vector-copy-numbers follow a Poisson distribution (Fehse et al., 2004). Thus, at the low transduction rate of
4%used, there is a very little likelihood that any transduced cell containsmore than one vector copy (Kustikova et al., 2003). To obtain
a pure population of barcoded cells, transduced cells were selected by puromycin treatment, which, however, could not impact the
vector copy number per cell. Moreover, we propose that double-barcoding would be evident by an equal, closed to 50:50, ratio of
two barcodes, but we don’t have indications for either bi- or poly-barcoding events. Barcode monoclonality in the 2nd-generation
explant cell lines is in favor of a single integration. To assess barcodes numbers empirically, we performed digital droplet PCR
(ddPCR) for copy number analysis of integrated barcodes in RGB32 cell line. A duplex assay against Illumina (i.e., BC32) sequences
and the human EpoR gene (chromosome 19) as a reference was performed. The ddPCR data clearly showed that on average there
was one (1.04) barcode present per two EpoR copies. Allowing a 10% error for ddPCR, the copy number would be between 0.94 and
1.14 per two EpoR genes. The data clearly demonstrated that RGB32 cells (or at least the vast majority of cells in the barcoded pop-
ulation) contained 1 barcode, as expected.
Generation of explant cell lines (see also Figure S6A)
To establish explant cell lines from tumor-bearing mice, tumors (or lymph nodes) collected in saline were immediately incubated
twice 5 minutes in Betadine (Mundipharma), washed twice in PBS, minced andmaintained in DMEM +GlutaMAX and 10% FBS sup-
plemented with Penicillin (100 IU/ml), Streptomycin (100 mg/ml) (BioConcept 4-01F00-H) and Amphotericin B (2.5 mg/ml) (GIBCO
15290026). Explant cell lines 293R, 407R and 411Rwere isolated from a series of recurrent tumors developing after surgical resection
of primary tumors generated by implantation of RGB32 cells in mice. Explant cell lines 578R, 581R-A, 582R, 584R and 585R were
isolated from recurrent tumors developing after surgical resection of tumors resulting from re-implantation of 293R, 407R or 411R
explants. Explant 581R-LNM was isolated from a lymph node metastasis following re-implantation of explant 407R.
Generation of cell lines by cell sorting
RGB32 cells were sorted in 3 separate fractions on a BD FACSAria III cell sorter at the Ludwig’s Flow Cytometry Facility using an anti-
CD10 antibody coupled to PE-Cy7 (Biolegend #312214) and the PE filter to measure mCherry positivity. This resulted in the gener-
ation of CD10high/PElow, CD10high/PEhigh and CD10low cells. CD10high/PElow and CD10high/PEhigh cells were mixed in accordance to
their original sorting ratio in order to reconstitute CD10high cells.
Cell culture of CAFs
Human cancer associated fibroblasts were established from a tumor biopsy from a patient undergoing surgery at the CHUV. The
procedure was approved by the Cantonal Department of the Swiss Ethics Committees and the relevant informed consent form
was signed by the patient. CAFs were cultured in DMEM/F-12 + GlutaMAX (GIBCO 31331028) supplemented with 10% FBS. Estab-
lished CAFs were transduced with pBabe-hTERT vector (kindly provided by Prof. G.-P. Dotto, UNIL) to generate immortalized CAF-T
cells.
Organotypic cell culture
Collagen plugs were prepared by mixing DMEM + GlutaMAX and 10% FBS with Collagen I (Ibidi # 50205) to a final concentration of
2.8 mg/ml. Collagen was neutralized with NaOH (10 mM final) and 1mL of collagen solution was transferred into a well from a 24-well
plate (TPP # 92424) and incubated at 37C for 30 minutes to allow the gel to set. 2x105 CAF-T cells were mixed with 1.6x105 CAL27
and either 4x104 RGB32 or 407R cells. The cell solution was then seeded on top of the collagen plug and incubated overnight. The
plugswere transferred on collagen-coated nylon discs placed on top of ametal grid inside a poly-HEMA (Sigma-Aldrich) coated 6 cmCell Reports 25, 2208–2222.e1–e7, November 20, 2018 e3
dish (TPP # 93060) filled with culture medium. The organotypes were allowed to develop for 13 days in culture before collection in 4%
PFA/PBS and processing as described below for tumor samples.
Surgical mouse model of HNSCC tumors
HumanHNSCC cells (CAL27, RGB32, 293R, 407R, 411R, CD10high or CD10low) were resuspended in 30 mL HBSS (GIBCO 14175053)
with or without addition of CAFs (see details in Figure S6B). The cell solution was mixed on ice with 20 mL BD Matrigel (Becton Dick-
inson 356234) and subcutaneously injected along the submental midline of 8-week-old female NMRI/Nude mice (JANVIER LABS, Le
Genest-Saint-Isle, France) to generate HNSCC tumors. Tumor volumewasmonitored using a Vernier caliper and calculated using the
modified ellipsoid formula: Volume = 1/2 * (Length * (Width)2). When primary tumors reached about 200-250 mm3, mice underwent
microsurgical tumor resection under general anesthesia. One day before surgery, paracetamol (Dafalgan; 2 mg/ml) was provided in
drinking water. Right before surgery, mice were anesthetized by intraperitoneal injection of a mixture of ketamine (50mg/kg) andme-
detomidine (Dorbene; 1 mg/kg). Resection of tumors was performed using iris scissors and microsurgical bipolar forceps (Erbotom;
ERBE SWISS AG). This surgical operation included a precise control of the surgical tumor bed by fluorescence imaging of tumor cells
using a Nikon SMZ1270i stereomicroscope. Tumors were dissected in pieces that were either collected by snap freezing in liquid
nitrogen for downstream DNA extraction and barcode analysis (Bar-Seq; see below) or further processed for histological evaluation,
fluorescence imaging (spectral analysis of RGB colors) and immunostainings. For experiments exploring the dissemination of cancer
cells beyond the border of the tumor, the adjacent muscles were dissected and collected in liquid nitrogen. The enrichment score
reported in Figure 3F was calculated by the log ratio of barcode counts (incremented by 0.01 pseudo-count) in the muscle compared
to the counts in the matching tumor. Wounds were closed with multifilament, 6.0 polyglycolic acid sutures (B. Braun Medical SA,
C0049607). Thereafter, 0.5 mL warm 0.9% NaCl was injected intraperitoneally and atipamezole (Alzane; 2.5 mg/kg) was injected
subcutaneously to antagonize medetomidine. Afterward, buprenorphine (0.05 mg/kg) was administrated subcutaneously, and
the mouse was placed on a heating pad until full recovery. During 7 days post-surgery, mice were treated with enrofloxacin
(600mg/L) and paracetamol (Dafalgan; 2mg/ml) in drinking water.Wounded skin was treated with Bepanthen cream until completion
of healing. Eight pairs were available for the analysis of matched primary and recurrent tumors (see details provided in Figure S6C).
Crizotinib treatment of tumor-bearing animals
From 14 days post-implantation up to the day of surgery (e.g., neo-adjuvant treatment), CAL27 tumor-bearingmicewere treated daily
by gavage with 12.5 mg/kg Crizotinib (PF-02341066, Active Biochem) diluted in drinking water (containing DMSO at a final concen-
tration of 1%). Mice additionally received a second treatment by gavage with 12.5 mg/kg Crizotinib diluted in drinking water from day
10 to 20 post surgery. Control mice only received the vehicle (1%DMSO, Sigma #41639). For this experiment (Figure S4I) a Log-rank
(Mantel-Cox) test was computed in GraphPad PRISM to determine the statistical significance level of the observed recurrence-free
survival benefit.
Histology and Immunofluorescence
For hematoxylin and eosin staining, tumors were fixed in formalin 10% (Sigma-Aldrich, HT501128) before embedding into paraffin.
For (immuno)fluorescence microscopy evaluation, tumors were fixed overnight in 4% paraformaldehyde (PFA) in PBS and trans-
ferred into 30% sucrose for a minimum of 4 hours before embedding into O.C.T. Compound Tissue-Tek (Sakura Finetek). For
Lyve-1 (RnD #mab-2125) and vimentin (Ab-247 (home-made) [Hartig et al., 1997]) immunostaining, PFA-fixed sectionswere permea-
bilized 10 minutes at RT with 0.1% Triton X-100 then blocked 30 minutes in PBS 0.5% BSA containing either 1% goat serum (for
Lyve-1) or 1% donkey serum (for vimentin) before incubation for 1 h at RT with primary antibodies diluted (1/200 respectively
1/1000) in Dako background-reducing agent (#S302283). After incubating 1 h at RT with secondary antibodies (goat anti-rat-A647
(Life technologies A-21247) or donkey anti-goat-A647 (Life technologies A-21447)) diluted 1/500 in Dako background-reducing
agent, sections were mounted in ProLong Gold antifade reagent with DAPI (Life technologies P-36931) and evaluated by fluores-
cence microscopy. Immunofluorescence on cell lines was performed with antibodies raised against SLUG (Cell signaling, C19G7
Rabbit mAb #9585) and ZEB1 (Cell signaling, D80D3 Rabbit mAb #3396).
DNA extraction and BC32 barcode retrieval
Genomic DNA (gDNA) was extracted from tumor tissue or cell pellets using QIAamp DNAmini kit (QIAGEN # 51304) following manu-
facturer instructions and including a digestion step with proteinase K (Applichem # A4392). DNA was eluted in 10 mM Tris-HCl
(pH 8.0). Extraction of DNA from muscle was performed with QiaAmp Fast DNA tissue kit (QIAGEN # 51404), and DNA was eluted
in manufacturer’s buffer ATE.
Starting with 200 ng (tumor or cell gDNA) or 1 mg (muscle gDNA) of template, barcodes from tumor or cell lines were retrieved by 30
PCR cycles (5min 95C, 30x [30 s 95C, 30 s 57C, 30 s 72C], 10min 68C) using high-fidelity Q5DNApolymerase (NEBM0491S) and
index primers from the NEBNext Multiplex Oligos for Illumina kits (NEB E7335, E7500 and E6609) to allow multiplexing of samples.
Barcode products were then purified with Agencourt AMPure XP beads (#A63880) using a one-step protocol with a beads ratio of
1.8x. For muscle DNA samples, barcodes were first pre-amplified by 15-30 PCR cycles using custom primers with phosphorothioate
bonds (MPLX-sPCR1: ACACTCTTTCCCTACACGACGCTCTTCCGATC-s-t, MPLX-sPCR2: GTGACTGGAGTTCAGACGTGTGCTCT
TCCGATC-s-t). Pre-amplified barcodes were purified with AMPure XP beads using a two-step protocol with beads ratios of 0.9x ande4 Cell Reports 25, 2208–2222.e1–e7, November 20, 2018
1.8x successively. Muscle gDNA derived barcodes were then indexedwith 25 additional PCR cycles using NEBNextMultiplex Oligos
for Illumina and purified with AMPure XP beads (one-step protocol at 1.8x ratio). Library quality and fragment sizes were assessed on
a Fragment Analyzer (Advanced Analytical) before high-throughput sequencing on a MiSeq platform (Illumina) at the Genomic Tech-
nologies Facility (GTF) of the University of Lausanne or on aMiniSeq platform (Illumina) at the Ludwig Institute for Cancer Research in
Lausanne. When a sample was expected to be monoclonal, purified barcodes were eventually sequenced by the conventional
Sanger method (Eurofins Genomics) to manage costs.
To ensure that the proof-reading activity of the Q5 DNA polymerase prevents barcode bias during PCR, amplification of an artificial
barcode-like template was controlled by NGS and showed a nearly constant low-rate of PCR errors even after 60 cycles (Figure S1D).
Laser microdissection
PFA-sucrose-OCT cryosections from five primary tumors where processed using ArcturusXT laser capture microdissection system
(Applied Biosystem). Each specimenwas cut in two successive radial areas from the center of the tumor to the periphery of the tumor,
and for each of the regions three serial sections were manually collected and pooled together after dissection by UV laser. Micro-
dissected sections were reverse-crosslinked by overnight incubation at 65C in 200 mL ChIP elution buffer (50 mM Tris-HCl
pH 8.0, 1% SDS, 10 mM EDTA). The next day, 3.5 mL of 300 mM CaCl2 in 10 mM Tris pH 8.0 and 2 mL of 20 mg/ml Proteinase K
were added to the solution and further incubated for 2 hours at 50C before DNA extraction using NucleoSpin Gel and PCR
Clean-up kit (Macherey-Nagel AG, #740609.5). 1 mg of carrier mouse DNA was added to enhance purification. DNA samples
were then normally processed for barcode retrieval and NGS library preparation.
RNA isolation and RT-qPCR
Total RNA from cell cultures was extracted with TRI Reagent (Sigma T-9424) and purified using Direct-zol RNA MiniPrep (Zymo
Research R2052) including a digestion step with DNase I (Roche 04 536 282 001). RNA (1 mg) was converted into cDNA using the
High Capacity RNA-to-cDNA Kit (Applied Biosystems, 4368814). Expression of ZEB1 or SNAI2 genes was quantified on an ABI
7500 Fast Real-Time PCR machine using Fast SYBR Green Master Mix (Applied Biosystems #4385618), 10 ng of template cDNA
and the following primer pairs at 0.2 mM: ZEB1-Q1F (50-TTACACCTTTGCATACAGAACCC-30) and ZEB1-Q2R (50-TTTACGATTAC
ACCCAGACTGC-30), or SNAI2-Q1 (50-CGAACTGGACACACATACAGTG-30) and SNAI2-Q2 (50-CTGAGGATCTCTGGTTGTGGT-30).
To calculate relative expression (RE) in each sample (compared to CAL27 expression), we used the formula RE = 2-(DDCt) were
DDCt corresponds to (DCtsample – DCtCAL27) with DCt being the Ct value of the target gene after normalization to GAPDH Ct value
(Ctgene - CtGAPDH). GAPDH was detected using the primers GAPDH-Q1 (5
0-ATGGGGAAGGTGAAGGTCG-30) and GAPDH-Q2
(50-GGGGTCATTGATGGCAACAATA-30).
Immunoblotting
Protein lysates were prepared in KLB lysis buffer supplemented with protease and phosphatase inhibitors (25 mM Tris-HCl (pH 7.4),
150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 10 mM sodium pyrophosphate, 10 mM b-glycerophosphate, 1 mM Pe-
fabloc SC (Roche 11 429 868 001), 0.02 mg/ml aprotinin, 10 mM sodium fluoride, 1 mM sodium orthovanadate) and were separated
by SDS-PAGE before transfer onto nitrocellulose Hybond membranes (GE / Amersham 10600003). After a blocking step with 5%
nonfat dry milk in PBS + 0.1% Tween 20 (PBS-T), membranes were incubated overnight with any of the following primary antibodies
diluted in PBS-T + 2.5%milk: E-Cadherin (Cell Signaling 3195), EGFR (Cell Signaling 2232), phospho-EGFR (Tyr1068) (Cell Signaling
2234), SMAD4 (Santa Cruz 7966) and phospho-SMAD2 (Ser465/467) (Cell Signaling 3108) all at 1/1’000, GAPDH at 1/40’000 (Merck
Millipore MAB374) and CD10 at 1/10 (hybridoma supernatant A12/G4, gift from Dr. Donata Rimoldi). HRP-conjugated secondary an-
tibodies (anti-mouse: DAKOP026002-2, anti-rabbit: DAKOP044801) were diluted at 1/50000 in PBS-T + 2.5%milk and the signal was
detected on a Vilber Fusion FX imager after incubation with Radiance Plus femtogram HRP Substrate (azure biosystems AC2103) or
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific 34087). Quantification of bands was performed using Image
Studio Lite Ver 5.2 (LI-COR Biosciences) and Fiji (https://fiji.sc/).
Sanger sequencing
Sanger sequencing of PCR products was performed by Eurofins Genomics (Ebersberg, Germany). Chromatogram profiles were in-
spected using sangerseqR package (v. 1.6.0) (Hill et al., 2014).
Analysis of BC32 barcode sequences (Bar-Seq)
BC32 barcodes consist of a repetitivemotif of 3 fixed nucleotides followed by 2 random nucleotides producing the subsequent back-
bone sequence: 50-CTANNCAGNNCTT NNCGANNCTANNCTT NNGGANNCTANNCAGNNCTT NNCGANNCTANNCTT NN
GGA NN CTA NN CAG NN-30. The BC32 barcode construct is based on mCherry-BC16 (Cornils et al., 2014) and follows the optimi-
zation previously described (Thielecke et al., 2017). The structure of the LeGO-eBFP2-2A-Puro-BC32 vector used in this study is
identical to the one shown in Thielecke et al. (2017), but the marker gene was replaced by a eBFP-2a-Puro cassette. The complete
vector sequence is available upon request to Kerstin Cornils and Boris Fehse.
Sequence processing and analysis were performed in R (https://www.R-project.org). All functions required for our Bar-Seq anal-
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reads that did not strictly match their expected multiplex index sequence (including 5 additional upstream and downstream constant
bases) were filtered out to avoid cross-sample contamination resulting from potential de-multiplexing errors. Next, reads matching
the BC32 backbone sequence (allowing for one substitution and/or one indel) were selected for downstream analysis. After careful
review of the sequences failing at the index or barcodematching step, some important additional barcode sequences were manually
authorized for downstream analysis when deemed necessary (e.g., for major clones differing from the barcode pattern by more than
one substitution).
These initial filtering steps were performed with ShortRead (v. 1.34.1) (Morgan et al., 2009) and BioString (v. 2.44.2). For each sam-
ple, the total number of read counts for each distinct BC32 sequence identified was then calculated. For clarity, we have arbitrarily
attributed a unique short name to each barcode (R1, ..., Rn) mainly based on their rank after sorting by decreasing frequency in the
parental cell line. The PCR error rate inherent to our system was evaluated in a cell-free environment limiting the rate of natural mu-
tations. To do so, a ‘‘barcode-like’’ synthetic oligonucleotide was designed by selecting a low occurrence BC32 real barcode and
shuffling its fixed-nucleotides triplets. The resulting oligonucleotide 50-CTA AAC AGA GCT ATG CTT GGC AGT TCT TCC CTA
ATC TTA CGG AGG CAG GTC GAG GGG ACT CTA CAC GAA GCT AAG CTT CT-30 was amplified by 30, 45 or 60 PCR cycles using
1 ng of template and multiplexing primers. The resulting PCR products were purified and sequenced on a MiSeq machine. The per-
centage of sequencing reads deviating from the oligonucleotide reference remained nearly constant despite the increasing number
of PCR cycles. For each sequenced sample, we used stringdist (v. 0.9.4.6) to calculate the restricted Damerau-Levenshtein distance
matrix between sequences and pooled any group of sequences differing by 12 or less mismatches under one individual barcode ID.
To optimize computation time, these initial processing steps were parallelized on Vital-IT (https://www.vital-it.ch/) cluster computers
(Vital-IT Center for high-performance computing of the Swiss Institute of Bioinformatics). For a global data analysis, barcode counts
for each sample were merged in one summary table (Table S1). To reduce noise, any read count below 10 was substituted by 0.
Finally, sample-wise frequencies and counts per million (CPMs) have been calculated for each barcode. Most plots were generated
using ggplot2 (v. 2.2.1) (Wickham, 2009), except Venn diagrams using VennDiagram (v. 1.6.17) and heatmaps using gplots (v. 3.0.1).
Dplyr (v. 0.7.2) and reshape2 (v. 1.4.2) were commonly used for data tidying purposes. Additional details on the Bar-Seq processing
can be found in the BC32BarSeq vignette.
Fluorescence imaging and spectral analysis
Eight-mm sections were cut from PFA/Sucrose/OCT embedded tumors (Mouse Pathology Facility, Lausanne) and mounted with a
coverslip using ProLong Diamond Antifade mounting media (Molecular Probes P36965). Sections were imaged with a Zeiss Axio
Imager Z1 microscope using fluorescence filters (Cellular Imaging Facility, Lausanne). Color spectrum graphs for each tumor image
were obtained with the color inspector 3D plugin (http://home.htw-berlin.de/barthel/ImageJ/ImageJ.htm) from Fiji using a top view
of the Hue Saturation Brightness (HSB) display with frequency weight set at maximum and perspective set at zero. This results in a
deconvoluted spectrum plot where each pixel from the original picture is plotted according to its hue value on the azimuthal coor-
dinate and its color saturation value on the radial coordinate. Black and white masks of the color spectra from matching primary
and recurrent tumors were further colored and merged using ‘‘mix RGB’’ nodes from Blender compositor (https://www.blender.
org) with blend types set as screen or multiply respectively. Amask for the overlap between primary and recurrent tumors was gener-
ated using a ‘‘mix RGB’’ node with blend type set as subtract on the previously merged images. Finally, quantification of the primary,
recurrent and overlapping binary masks was performed in R with a custom script computing the sum of all black pixels in eachmask.
Exome sequencing, variants and copy number variation analysis
Exome sequencing was performed on 3 control cell lines (CAL27, RGB, BC32), 11 recurrence-derived explant cell lines (293R, 407R,
411R, 411R/VeHi, 411R/VeLo, 578R, 581R-A, 581R-LNM, 584R, 585R and 673R) and one primary tumor derived explant cell line
(673). Variant calling has been performed using the standard BWA-Picard-GATK pipeline. Briefly, exomes were captured using Agi-
lent SureSelect Human All Exon v5 enrichment kits and sequenced on Illumina HiSeq 2500 platform (for control cell lines and 293R,
407R, 411R explant cell lines) or HiSeq 4000 platform (for all other explant cell lines). Purity-filtered reads were trimmed for adapters
and quality with FastqMcf. (v. 1.1.2, https://github.com/ExpressionAnalysis/ea-utils), and aligned to the human genome (hg19) using
BWA-MEM (v. 0.7.12) (Li and Durbin, 2009). BAM files were further processed with GATK (v. 3.7) and LoFreq (v. 2.1.2) (Wilm et al.,
2012) for realignment around indels and base quality score recalibration (Van der Auwera et al., 2013). Recalibrated BAM files were
then used to detect explant-specific variants with LoFreq. Variants in mitochondrial DNA were called using MuTect2 from the GATK
package by explicitly providing ‘‘chrM’’ as the targets interval parameter. De novomutations were called using the reference RGB32
BAM file as normal input (normal run) whereas ‘‘wild-typing’’ genotypes were detected by inverting the inputs hence using RGB32
BAM file as tumor input (reverse run). Reads coverage for each variant position were calculated from recalibrated BAM files using
GATK’s HaplotypeCaller and custom BED files. Downstream analysis was performed in R. Exome reference BED files (SureSelect
V5) were downloaded from Agilent SureDesign website (https://earray.chem.agilent.com/suredesign) and loaded in a GRanges ob-
ject using GenomicRanges (v. 1.28.4) (Lawrence et al., 2013). The overlap between explant variants and exons referenced in
SureSelect V5 BED file was then detected with findOverlap function. Variants were annotated with predictCoding function from
the VariantAnnotation package (v. 1.22.3) (Obenchain et al., 2014) using BSgenome.Hsapiens.UCSC.hg19 (v. 1.4.0). Mitochondrial
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Copy number analysis was performed on recalibrated BAMfiles with CODEX (v. 1.8.0) (Jiang et al., 2015) following the default pipe-
line and settings described in the vignette. Iterating through all chromosomes, normalization of read depth was performed by the
normalize2 function with normal_index parameter pointing at CAL27, CRGB and RGB32 samples in order to detect copy number
variation under the case-control setting. Segmentation was performed with DNAcopy (v. 1.50.0) with the default settings and using
as input the binary log ratios of raw read depth compared to normalized read depth calculated by CODEX (log2(Y/lhat)) after smooth-
ing the data using ksmooth algorithm (R stats package) with a bandwidth parameter k = 10. Each segment with a mean variation
above 0.2 or below 0.2 was annotated with the names of genes integrated in the segment using GenomicRanges’ findOverlap
and BSgenome.Hsapiens.UCSC.hg19. Dplyr (v. 0.7.2) and reshape2 (v. 1.4.2) were commonly used for data tidying purposes.
The resulting list of explant-specific CNVs is available in Table S3.
Membrane proteomics
Membrane proteomics was performed on three control cell lines (CAL27, CRGB, RGB32) and three recurrent explant cell lines (293R,
407R, 411R) by mass spectrometry at the Clinical and Biomedical Proteomics Group of the University of Leeds. The modified pro-
cedure of Bordier for preparation of the enriched membrane protein fractions, the STrap-based tryptic digestion with the following
mass spectrometric processing were performed as previously described (Zougman et al., 2014).
QUANTIFICATION AND STATISTICAL ANALYSIS
Mathematical methods
Statistical simulations were done using the statistic software R (Version – 3.4.1) and the binomial functions from the stats package.
Posterior probabilities were calculated according to a binomial distribution function in which n equals the number of remaining tumor
cells and p resembling the initial frequency of RTICs within the primary tumor. The simulations were done for an initial RTIC concen-
tration of p = 25% and a surgical tumor removal of 99.9996% of initially 250’000’000 cells (n = 1000). Figure 3D was generated using
the statistic software R (Version 3.4.2) and the stats package (Version 3.4.2). The two different scenarios were initialized with 400
clones where individual clone sizes were sampled from a Weibull distribution (rweibull). Furthermore, the position of each single
cell within the spatially uniform scenario was sampled from a uniform distribution (runif) as well as the seed of each clonal patch within
the spatially confined scenario. The individual cells of each clone, making up the patches within the 2nd scenario, were normally
distributed around the respective seed (rnorm). We selected a convex hull based on the patchy setting in order to guarantee a
compact point cloud (tumor). This boundary was then identically applied to the homogeneous setting. Finally, the convex hull was
shrunk so that the ‘‘inner mass’’ of the simulated tumor can be extracted.
Statistics
Statistical parameters including the definitions and exact values of n (e.g., number of samples, number of fields quantified, etc.), dis-
tributions and deviations are reported in the figures and corresponding figure legends.Wherever possible, individual data points were
overlaid on boxplots to obtain a full representation of the data distribution. Unless otherwise stated, two-sample t tests were used to
compute the statistical difference between two groups (in R). Data was judged to be statistically significant when p < 0.05.
DATA AND SOFTWARE AVAILABILITY
The R package used to generate a table of counts/frequencies from raw sequence data can be obtained at the following address:
https://github.com/vroh/BC32_BarSeq. The accession number for the Fastq files resulting from exome sequencing reported in
this paper is European Nucleotide Archive (ENA): PRJEB25375.Cell Reports 25, 2208–2222.e1–e7, November 20, 2018 e7
